I-131 Metaiodobenzylguanidine Therapy: It Takes a Village; The Experience Gained at Three Institutions (007)

Despite aggressive treatment, patients with high-risk neuroblastoma have a 40%-60% chance of suffering a relapse. Recent improvements in survival have resulted from changes in treatment during consolidation (tandem myeloablative stem cell transplants) and post-consolidation (immunotherapy) time periods. The neuroblastoma community has been struggling to identify treatments that can be integrated into induction therapy with the goal of further improving survival rates. Consequently, I-131 Metaiodobenzylguanidine (I-131 MIBG) has been moved to the induction treatment period due to its history of success in the treatment of patients with relapsed refractory disease (approximately 40% of patients have a favorable response to treatment with I-131 MIBG).

Due to this change in practice, there has been a substantial increase in the number of I-131 MIBG therapies occurring throughout institutions worldwide. Our presentation will combine the experiences gained from three institutions providing I-131 MIBG therapy to patients: The Children’s Hospital of Philadelphia, PA; Atrium Health Levine Children’s Hospital in Charlotte, NC; and Comer Children’s Hospital in Chicago, IL. We will include discussions about advanced practice providers, nursing, nuclear medicine, social work, radiation safety, and child life. We will discuss the history of and rationale for I-131 MIBG therapy, as well as the need for a multidisciplinary team to safely provide this treatment. We will share the experiences gained from a newly created I-131 MIBG program from the time of the program’s inception to their newly functioning program. We will discuss a study completed to better understand the experiences of children treated with I-131 MIBG therapy as reported by patients, parents, and nurses. We will utilize case studies throughout our session to enhance the presentation. Our goal is to educate those who have patients who are being referred to other institutions for treatment, as well as those who are currently treating patients with I-131 MIBG.

Speaker(s):

Jennifer Saggio, MSN CRNP
Dawn Bartock, MSN CPNP CPHON®
Sage Heyman, LSW
Dennis Reid, BSN CPHON®
Alyssa Yost, BSN RN

ssa Yost, BSN RN
Fee:
$110 for APHON members
$140 for non-members
CNE Hours:
3.25